drugset / Trial / NCT00369395

A Study of Volociximab in Metastatic Melanoma

NCT00369395

Phase 2 Terminated 19 enrolled Abbott Biogen · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab. Pharmacokinetics and mechanism of action will also be evaluated.

Timeline

Start
2006-12
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Volociximab Monoclonal antibody 15 mg/kg Intravenous

Indications